Potential Deleterious Effects of Vasopressin in Chronic Kidney Disease and Particularly Autosomal Dominant Polycystic Kidney Disease

被引:28
作者
Meijer, E. [1 ]
Boertien, W. E. [1 ]
Zietse, R. [2 ]
Gansevoort, R. T. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands
[2] Erasmus MC, Dept Nephrol, Rotterdam, Netherlands
关键词
Vasopressin; Copeptin; Chronic kidney disease; Autosomal dominant polycystic kidney disease; Albuminuria; Proteinuria; Glomerular filtration rate; RENAL CONCENTRATING CAPACITY; GLOMERULAR-FILTRATION-RATE; RENIN-ANGIOTENSIN SYSTEM; RECEPTOR ANTAGONISTS; DIABETES-MELLITUS; ANTIDIURETIC ACTION; PLASMA VASOPRESSIN; SURROGATE MARKER; BRATTLEBORO RATS; SODIUM-EXCRETION;
D O I
10.1159/000326902
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The antidiuretic hormone vasopressin is crucial for regulating free water clearance in normal physiology. However, it has also been hypothesized that vasopressin has deleterious effects on the kidney. Vasopressin is elevated in animals and patients with chronic kidney disease. Suppression of vasopressin activity reduces proteinuria, renal hypertrophy, glomerulosclerosis and tubulointerstitial fibrosis in animal models. The potential detrimental influence of vasopressin is probably mediated by its effects on mesangial cell proliferation, renin secretion, renal hemodynamics, and blood pressure. In this review, we discuss the increasing body of evidence pointing towards the contribution of vasopressin to chronic kidney disease progression in general and to autosomal dominant polycystic kidney disease in particular. These data allude to the possibility that interventions directed at lowering vasopressin activity, for example by the administration of vasopressin receptor antagonists or by drinking more water, may be beneficial in chronic kidney disease. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码:235 / 244
页数:10
相关论文
共 50 条
[41]   Autosomal dominant polycystic kidney disease: Disrupted pathways and potential therapeutic interventions [J].
Malekshahabi, Talieh ;
Rad, Niloofar Khoshdel ;
Serra, Andreas L. ;
Moghadasali, Reza .
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (08) :12451-12470
[42]   Relationship between disease awareness and severity of kidney disease in autosomal dominant polycystic kidney disease patients [J].
Dogan, Ege ;
Eren, Necmi ;
Ozcan, Seyda Gul ;
Altunoren, Orcun ;
Gungor, Ozkan ;
Dheir, Hamad ;
Tanrisev, Mehmet ;
Kocyigit, Hafsa ;
Yildiz, Abdulmecit ;
Kocyigit, Ismail ;
Seyahi, Nurhan ;
Tatar, Erhan .
THERAPEUTIC APHERESIS AND DIALYSIS, 2023, 27 (01) :117-122
[43]   Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience [J].
Abdullah Ozkok ;
Timur Selcuk Akpinar ;
Fatih Tufan ;
Nilufer Alpay Kanitez ;
Mukremin Uysal ;
Metban Guzel ;
Yasar Caliskan ;
Sabahat Alisir ;
Halil Yazici ;
Tevfik Ecder .
Clinical and Experimental Nephrology, 2013, 17 :345-351
[44]   Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience [J].
Ozkok, Abdullah ;
Akpinar, Timur Selcuk ;
Tufan, Fatih ;
Kanitez, Nilufer Alpay ;
Uysal, Mukremin ;
Guzel, Metban ;
Caliskan, Yasar ;
Alisir, Sabahat ;
Yazici, Halil ;
Ecder, Tevfik .
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2013, 17 (03) :345-351
[45]   Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease [J].
Luis Gorriz, Jose ;
Arroyo, David ;
D'Marco, Luis ;
Torra, Roser ;
Tomas, Patricia ;
Jesus Puchades, Maria ;
Panizo, Nayara ;
Pantoja, Jonay ;
Montomoli, Marco ;
Luis Llisterri, Jose ;
Pallares-Carratala, Vicente ;
Manuel Valdivielso, Jose .
BMC NEPHROLOGY, 2021, 22 (01)
[46]   Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease [J].
Torres, Vicente E. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (01) :30-34
[47]   Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease [J].
José Luis Gorriz ;
David Arroyo ;
Luis D’Marco ;
Roser Torra ;
Patricia Tomás ;
María Jesús Puchades ;
Nayara Panizo ;
Jonay Pantoja ;
Marco Montomoli ;
José Luis Llisterri ;
Vicente Pallares-Carratalá ;
José Manuel Valdivielso .
BMC Nephrology, 22
[48]   Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease [J].
Torres, Vicente E. ;
Chapman, Arlene B. ;
Devuyst, Olivier ;
Gansevoort, Ron T. ;
Perrone, Ronald D. ;
Koch, Gary ;
Ouyang, John ;
McQuade, Robert D. ;
Blais, Jaime D. ;
Czerwiec, Frank S. ;
Sergeyeva, Olga .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1930-1942
[49]   Assessment of Adrenal Functions in Patients with Autosomal Dominant Polycystic Kidney Disease [J].
Tufan, F. ;
Uslu, B. ;
Cekrezi, B. ;
Uysal, M. ;
Alpay, N. ;
Turkmen, K. ;
Disci, R. ;
Ozbey, N. C. ;
Ecder, T. .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2010, 118 (10) :741-746
[50]   Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease [J].
Blijdorp, Charles J. ;
Severs, David ;
Musterd-Bhaggoe, Usha M. ;
Gansevoort, Ronald T. ;
Zietse, Robert ;
Hoorn, Ewout J. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (12) :2248-2255